Consider This Before Taking a Position in InMed Pharmaceuticals (INM)

InMed Pharmaceuticals marked a -0.94% change today, compared to 0.03% for the S&P 500. Is it a good value at today's price of $1.05? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

  • InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies.

  • InMed Pharmaceuticals belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 24.45 and an average price to book (P/B) of 4.16

  • The company's P/B ratio is 0.198

  • InMed Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -0.06 based on its trailing 12 month price to earnings (EPS) of $-17.77 per share

  • Its forward P/E ratio is -0.17, based on its forward earnings per share (EPS) of $-6.25

  • Over the last four years, InMed Pharmaceuticals has averaged free cash flows of $-12.7 Million which are declining at an arithmetic annual average of -29.77%

  • INM's gross profit margins have averaged -2837.6 % over the last four years and during this time they had a growth rate of 50.44 % and a coefficient of variability of 144 %.

  • InMed Pharmaceuticals has moved 40.96% over the last year compared to -7.46% for the S&P 500 -- a difference of 48.42%

  • INM has an average analyst rating of hold and is -94.75% away from its mean target price of $20.0 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.